Salim Syed
Stock Analyst at Mizuho
(0)
# 3881
Out of 5,253 analysts
76
Total ratings
42.59%
Success rate
-0.76%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
WAVE Life Sciences | Maintains: Outperform | 19 22 | 12.05 | 82.57% | 5 | Nov 21, 2024 | |
Nkarta | Maintains: Outperform | 20 16 | 2.29 | 598.69% | 7 | Nov 21, 2024 | |
Gilead Sciences | Maintains: Outperform | 90 100 | 95.94 | 4.23% | 6 | Nov 21, 2024 | |
Cytokinetics | Maintains: Outperform | 99 103 | 49.13 | 109.65% | 6 | Nov 21, 2024 | |
Biogen | Maintains: Outperform | 251 207 | 146.95 | 40.86% | 15 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 113 163 | 91.68 | 77.79% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 25 18 | 8.12 | 121.67% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 223 235 | 281.19 | -16.43% | 7 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 34 | 21.27 | 59.85% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 82 99 | 41.78 | 136.96% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 60 53 | 36.35 | 45.8% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 12 6 | 2.28 | 163.16% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 28 21 | 1.07 | 1862.62% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 168 36 | 14.42 | 149.65% | 1 | Nov 16, 2022 |